Clinical observation of Kuntai capsule combined with Estradiol tablets/Estradiol dydrogesterone tablets in the treatment of diminished ovarian reserve
- VernacularTitle:坤泰胶囊联合雌二醇片/雌二醇地屈孕酮片治疗卵巢储备功能减退的临床观察
- Author:
Xiuping WANG
1
;
Xianwei QIAO
2
;
Bing XU
3
Author Information
1. Dept. of Traditional Chinese Medicine，Nanyang First People’s Hospital，Henan Nanyang 473000，China
2. Dept. of Clinical Laboratory，Nanyang First People’s Hospital，Henan Nanyang 473000，China
3. Dept. of Traditional Chinese Medical Gynecology，Nanyang Second People’s Hospital，Henan Nanyang 473000，China
- Publication Type:Journal Article
- Keywords:
Kuntai capsules;
diminished ovarian reserve;
estradiol;
dydrogesterone;
ovarian reserve;
lymphocytes;
sex
- From:
China Pharmacy
2025;36(5):589-593
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe the clinical efficacy， safety and recurrence of Kuntai capsules combined with Estradiol tablets/Estradiol dydrogesterone tablets in the treatment of diminished ovarian reserve （DOR） as well as their effects on ovarian reserve function， sex hormones， and lymphocyte subsets. METHODS A retrospective analysis was conducted on the clinical data of 165 DOR patients in Nanyang First People’s Hospital. Among them， 80 patients who received Estradiol tablets/Estradiol dydrogesterone tablets （take one tablet per day according to the medication sequence on the instruction） were included in the control group， while 85 patients who additionally took Kuntai capsules （2.0 g per dose， three times daily） were included in the observation group. The treatment duration for both groups was three months. Clinical efficacy， the incidence of adverse drug reaction （ADR）， recurrence rate， and changes in Traditional Chinese Medicine （TCM） syndrome scores， ovarian reserve function indicators [anti-Müllerian hormone （AMH）， inhibin B （INHB）， antral follicle count （AFC）， endometrial thickness， and ovarian volume]， sex hormones [follicle-stimulating hormone （FSH）， luteinizing hormone （LH）， and estradiol （E2）]， and T lymphocyte subsets （CD3 +， CD4 +， CD8 +， and CD4 +/CD8 +） were compared before and after treatment. RESULTS The cure and significant improvement rate in the observation group was significantly higher than in the control group （82.35% vs. 65.00%， P＜0.05）. Compared to baseline levels， both groups showed significant reductions in TCM syndrome scores， FSH， LH， CD3+ and CD8+ levels after treatment， while AMH， INHB， E2， CD4 +， CD4 +/CD8 +， AFC， endometrial thickness， and ovarian volume significantly increased （P＜0.05）. The degree of improvement in these indicators was significantly greater in the observation group than in the control group （P＜0.05）. There was no significant difference in the total incidence of ADR between the two groups（P＞ 0.05）. However， the recurrence rate within six months post-treatment was significantly lower in the observation group compared to the control group （5.88% vs. 21.25%， P＜0.05）. CONCLUSIONS Kuntai capsules combined with Estradiol tablets/ Estradiol dydrogesterone tablets have a significant therapeutic effect on DOR， which can improve ovarian reserve function of the patient， regulate sex hormone levels and T lymphocyte subsets， and reduce recurrence rates， with a high safety profile.
